New radiation technique aims to shield airways and preserve lung function
NCT ID NCT07679607
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatment. About 70 participants will receive either standard or airway-sparing radiation, and their lung function will be measured at 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
airway-sparing radiation therapy (INSPIRE RT)
What this could lead to
If successful, this approach could help lung cancer patients preserve more lung function and improve quality of life after radiation therapy.
What could go wrong
This is a Phase 2 trial with 70 participants, so results are preliminary. The new planning method may not significantly improve breathing or could increase other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••